The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence ...

Read about Sionna Therapeutics Inc (SION:XNAS) stock and today's latest news and financial updates.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...

Sionna Therapeutics, Inc. (SION) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 million Series B in 2022.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Sionna Therapeutics, Inc. OverviewBiotechnology / Healthcare Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic ...